Business UpdateMay 14, 2026, 04:18 PM
AEON Biopharma details ABP-450 biosimilar strategy for $3.5B market
AI Summary
AEON Biopharma, Inc. made a corporate presentation available detailing its strategy to develop ABP-450 as the first clinically substitutable therapeutic alternative to BOTOX®. The company aims to unlock a $3.5 billion neurotoxin market by pursuing full-label extrapolation under the FDA's 351(k) biosimilar pathway. The presentation highlights strong analytical data, including 100% amino acid sequence identity and genetic/formulation parity with BOTOX®, and outlines a clear regulatory path following positive FDA Type 2a feedback.
Key Highlights
- Advancing ABP-450 as the first clinically substitutable BOTOX® biosimilar for a $3.5B neurotoxin market.
- ABP-450 targets full-label extrapolation under FDA's 351(k) pathway for all BOTOX® therapeutic indications.
- Analytical data shows 100% amino acid sequence identity and genetic/formulation parity with BOTOX®.
- January FDA Type 2a meeting provided a clear framework; Type 2b meeting planned for 2H26.
- The U.S. therapeutic neurotoxin market is projected to grow from $3.5B in 2026 to $5.1B in 2031.
- ABP-450 aims to improve physician economics and provide cost savings for payers.
- Company led by Rob Bancroft (CEO, former BOTOX® leader) and John Bencich (CFO).
- Shares outstanding are ~26.3M, with ~18.4M outstanding warrants.
Price Impact
More from AEON